Detalles de la búsqueda
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38084760
2.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Lancet Oncol
; 2024 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38889735
3.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood
; 136(8): 936-945, 2020 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32325490
4.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34529931
5.
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Blood
; 134(5): 421-431, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31113777
6.
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Blood
; 128(14): 1821-1828, 2016 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27531679
7.
Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study.
Haematologica
; 108(2): 621-626, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36263839
8.
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Haematologica
; 106(8): 2257-2260, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33657786
9.
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.
Br J Haematol
; 186(3): e35-e39, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30931524
10.
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching.
EJHaem
; 2(1): 66-80, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35846097
11.
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 21(10): 701-710, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34274290
12.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Lancet Haematol
; 7(12): e874-e883, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33242444
13.
The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia.
J Support Oncol
; 6(6): 283-90, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18724539
14.
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
J Support Oncol
; 6(1): 18-25, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18257397
15.
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
Clin Cancer Res
; 23(14): 3544-3551, 2017 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28213364
16.
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Eur Urol
; 70(6): 963-970, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27160947
17.
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma.
Clin Cancer Res
; 21(8): 1843-50, 2015 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25628399
18.
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Target Oncol
; 10(1): 111-23, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24928772
Resultados
1 -
18
de 18
1
Próxima >
>>